ZA201001339B - Antibody targeting osteoclast-related protein Siglec-15 - Google Patents

Antibody targeting osteoclast-related protein Siglec-15

Info

Publication number
ZA201001339B
ZA201001339B ZA201001339A ZA201001339A ZA201001339B ZA 201001339 B ZA201001339 B ZA 201001339B ZA 201001339 A ZA201001339 A ZA 201001339A ZA 201001339 A ZA201001339 A ZA 201001339A ZA 201001339 B ZA201001339 B ZA 201001339B
Authority
ZA
South Africa
Prior art keywords
related protein
antibody targeting
protein siglec
targeting osteoclast
osteoclast
Prior art date
Application number
ZA201001339A
Other languages
English (en)
Inventor
Yoshiharu Hiruma
Eisuke Tsuda
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40549216&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201001339(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of ZA201001339B publication Critical patent/ZA201001339B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
ZA201001339A 2007-10-11 2010-02-24 Antibody targeting osteoclast-related protein Siglec-15 ZA201001339B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007265420 2007-10-11

Publications (1)

Publication Number Publication Date
ZA201001339B true ZA201001339B (en) 2010-10-27

Family

ID=40549216

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA201001339A ZA201001339B (en) 2007-10-11 2010-02-24 Antibody targeting osteoclast-related protein Siglec-15

Country Status (25)

Country Link
US (5) US8546540B2 (ja)
EP (2) EP2907826B1 (ja)
JP (4) JPWO2009048072A1 (ja)
KR (2) KR101577935B1 (ja)
CN (2) CN108130327A (ja)
AU (2) AU2008311698C1 (ja)
BR (1) BRPI0818437B8 (ja)
CA (2) CA2698326C (ja)
CY (1) CY1116432T1 (ja)
DK (1) DK2206727T3 (ja)
ES (2) ES2540733T3 (ja)
HK (2) HK1145847A1 (ja)
HR (1) HRP20150485T1 (ja)
HU (1) HUE025262T2 (ja)
IL (2) IL204607A (ja)
MX (1) MX2010003884A (ja)
NZ (1) NZ583397A (ja)
PL (1) PL2206727T3 (ja)
PT (1) PT2206727E (ja)
RU (2) RU2475499C2 (ja)
SG (2) SG187523A1 (ja)
SI (1) SI2206727T1 (ja)
TW (1) TWI511740B (ja)
WO (1) WO2009048072A1 (ja)
ZA (1) ZA201001339B (ja)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI359026B (en) 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
US8168181B2 (en) * 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
JP5173838B2 (ja) 2006-02-13 2013-04-03 アレシア・バイオセラピューティクス・インコーポレーテッド 骨リモデリングのプロセスと関係があるポリヌクレオチドおよびポリペプチド配列
CA2698326C (en) 2007-10-11 2015-03-17 Daiichi Sankyo Company, Limited Antibody targeting osteoclast-related protein siglec-15
MX2011007342A (es) 2009-04-09 2011-07-21 Daiichi Sankyo Co Ltd Anticuerpo anti-lectina similar a inmunoglobulina de union a acido sialico-15.
MX2013003828A (es) * 2010-10-05 2013-06-28 Daiichi Sankyo Co Ltd Anticuerpo dirigido a la proteina lectina tipo inmunoglobulina de union a acido sialico-15 relacionada con osteoclastos.
US20130280260A1 (en) * 2010-10-13 2013-10-24 Tokyo Women's Medical University Osteoclastogenesis inhibitor containing anti-vdac antibody
CA2848074A1 (en) * 2011-09-09 2013-03-14 Medimmune Limited Anti-siglec-15 antibodies and uses thereof
US20150125470A1 (en) 2012-03-30 2015-05-07 Daiichi Sankyo Company, Limited Novel anti-siglec-15 antibody
KR20150003170A (ko) 2012-03-30 2015-01-08 다이이찌 산쿄 가부시키가이샤 ＣＤＲ 개변 항 Ｓｉｇｌｅｃ-15 항체
CA2928851A1 (en) 2012-07-19 2014-01-23 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
EP3061818B1 (en) 2013-09-30 2020-12-16 Daiichi Sankyo Company, Limited Anti-lps o11 antibody
WO2015150326A1 (en) * 2014-03-31 2015-10-08 Universiteit Gent A method of treating bone disease
IL290959B2 (en) 2015-06-29 2023-04-01 Daiichi Sankyo Co Ltd Preparations containing antibody-drug conjugates and methods for their production
AU2017330346A1 (en) 2016-09-21 2019-02-21 Nextcure, Inc. Antibodies for Siglec-15 and methods of use thereof
EP4360714A3 (en) * 2016-09-21 2024-07-24 Nextcure, Inc. Antibodies for siglec-15 and methods of use thereof
WO2018147245A1 (ja) 2017-02-07 2018-08-16 第一三共株式会社 抗ｇｐｒｃ５ｄ抗体及び該抗体を含む分子
TWI782000B (zh) 2017-03-30 2022-11-01 日商第一三共股份有限公司 抗ｇｐｒ２０抗體、其製造方法及其應用
WO2019004487A1 (ja) 2017-06-30 2019-01-03 国立大学法人北海道大学 成長障害を生じない小児骨粗鬆症治療薬
SG11202000759XA (en) 2017-07-27 2020-02-27 Daiichi Sankyo Co Ltd Anti-cd147 antibody
CA3099900A1 (en) 2018-05-31 2019-12-05 Daiichi Sankyo Company, Limited Anti-human tlr7 antibody
AU2019311596A1 (en) 2018-07-27 2021-01-28 Daiichi Sankyo Company, Limited Protein recognizing drug moiety of antibody-drug conjugate
CN111378043B (zh) * 2020-02-19 2021-02-09 南京医科大学 一种具有中和作用的人鼠嵌合抗Siglec-15全分子IgG及其制备方法和应用
CN112159475B (zh) * 2020-10-10 2021-04-30 南京凯地生物科技有限公司 Siglec-15单克隆抗体及其应用
CN112625132B (zh) * 2021-01-15 2022-08-02 沈阳荣欣生物制药科技有限公司 纳米抗体及其编码基因、表达载体、宿主细胞和应用
CN114957468A (zh) * 2021-02-25 2022-08-30 石药集团巨石生物制药有限公司 一种抗Siglec15抗体及其用途
CN112961214B (zh) * 2021-03-19 2022-08-02 江苏元本生物科技有限公司 一种靶向Siglec-15的噬菌体多肽
CN112979761B (zh) * 2021-03-19 2021-12-10 江苏元本生物科技有限公司 一种靶向Siglec-15的噬菌体多肽
CN113577283A (zh) * 2021-07-19 2021-11-02 河北医科大学第三医院 Siglec-15抑制剂在制备防治骨巨细胞瘤药物中的应用
CN114807052A (zh) * 2022-06-07 2022-07-29 江苏亲科生物研究中心有限公司 Siglec15单克隆抗体及其制备方法和用途
WO2024022008A1 (zh) * 2022-07-26 2024-02-01 北京东方百泰生物科技股份有限公司 一种抗Siglec-15单克隆抗体、其抗原结合片段及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5116828A (en) * 1989-10-26 1992-05-26 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of osteoporosis
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0605522T3 (da) 1991-09-23 2000-01-17 Medical Res Council Fremgangsmåde til fremstilling af humaniserede antistoffer
DE69233782D1 (de) 1991-12-02 2010-05-20 Medical Res Council Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5660827A (en) * 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
CA2131151A1 (en) 1992-03-24 1994-09-30 Kevin S. Johnson Methods for producing members of specific binding pairs
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
AU690171B2 (en) 1993-12-03 1998-04-23 Medical Research Council Recombinant binding proteins and peptides
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
DE19653646A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
WO1998046644A1 (en) 1997-04-15 1998-10-22 Snow Brand Milk Products Co., Ltd. Novel protein and process for producing the same
JP4542704B2 (ja) 1998-05-08 2010-09-15 富山化学工業株式会社 新規なスピロ化合物またはその塩、それらを含有する自己免疫疾患の予防・治療剤およびａｐ−１阻害剤
MXPA03000514A (es) * 2000-07-21 2003-10-06 Bristol Myers Squibb Co Lectinas relacionadas a inmunoglobulina con enlace a acido sialico y usos de los mismos.
AU2002233994A1 (en) 2000-11-08 2002-05-21 Incyte Genomics, Inc. Secreted proteins
US7608704B2 (en) * 2000-11-08 2009-10-27 Incyte Corporation Secreted proteins
WO2002064771A1 (fr) 2001-02-15 2002-08-22 Mochida Pharmaceutical Co., Ltd. Nouvelle molecule d'adhesion cellulaire specifique de leucocyte active
DK2270052T3 (en) * 2001-06-26 2018-07-02 Amgen Inc Antibodies to OPGL
US20050107588A1 (en) 2001-11-13 2005-05-19 Duggan Brendan M. Receptors and membrane-associated proteins
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
MXPA04009681A (es) * 2002-04-05 2005-01-11 Amgen Inc Anticuerpos humanos neutralizantes anti-ligando de osteoprotegerina como inhibidores selectivos de la ruta del ligando de osteoprotegerina.
EA013225B1 (ru) 2003-01-07 2010-04-30 Симфоген А/С Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток
TWI359026B (en) 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
JP4633491B2 (ja) * 2004-02-12 2011-02-16 第一三共株式会社 破骨細胞関連タンパク質を標的とした抗体
US7405037B2 (en) 2004-05-07 2008-07-29 Lonza Walkersville, Inc. Methods and tools for detecting collagen degradation
CN101035807A (zh) * 2004-06-09 2007-09-12 泰勒公司 Siglec－6相关疾病的诊断和治疗
JP4604184B2 (ja) 2005-07-12 2010-12-22 独立行政法人産業技術総合研究所 新規糖鎖認識蛋白質及びその遺伝子
GB0521991D0 (en) * 2005-10-28 2005-12-07 Univ Dundee Siglec-9 binding agents
JP5173838B2 (ja) 2006-02-13 2013-04-03 アレシア・バイオセラピューティクス・インコーポレーテッド 骨リモデリングのプロセスと関係があるポリヌクレオチドおよびポリペプチド配列
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CA2698326C (en) 2007-10-11 2015-03-17 Daiichi Sankyo Company, Limited Antibody targeting osteoclast-related protein siglec-15
MX2011007342A (es) 2009-04-09 2011-07-21 Daiichi Sankyo Co Ltd Anticuerpo anti-lectina similar a inmunoglobulina de union a acido sialico-15.
DK2585349T3 (en) 2010-06-23 2015-03-23 Creissels Technologies Systems with transmission lines and remote-controlled vehicle without suspension
MX2013003828A (es) 2010-10-05 2013-06-28 Daiichi Sankyo Co Ltd Anticuerpo dirigido a la proteina lectina tipo inmunoglobulina de union a acido sialico-15 relacionada con osteoclastos.
US20150125470A1 (en) 2012-03-30 2015-05-07 Daiichi Sankyo Company, Limited Novel anti-siglec-15 antibody
KR20150003170A (ko) 2012-03-30 2015-01-08 다이이찌 산쿄 가부시키가이샤 ＣＤＲ 개변 항 Ｓｉｇｌｅｃ-15 항체

Also Published As

Publication number Publication date
HUE025262T2 (en) 2016-02-29
HK1209135A1 (en) 2016-03-24
AU2008311698B2 (en) 2011-12-01
CA2698326C (en) 2015-03-17
ES2677246T3 (es) 2018-07-31
AU2012201263B9 (en) 2017-06-01
IL234078A0 (en) 2014-09-30
IL204607A (en) 2016-03-31
BRPI0818437A8 (pt) 2019-01-15
EP2206727A4 (en) 2011-03-02
US9815899B2 (en) 2017-11-14
WO2009048072A1 (ja) 2009-04-16
CY1116432T1 (el) 2017-02-08
BRPI0818437A2 (pt) 2015-05-12
AU2012201263B2 (en) 2017-04-20
BRPI0818437B8 (pt) 2021-05-25
DK2206727T3 (en) 2015-07-06
ES2540733T3 (es) 2015-07-13
RU2475499C2 (ru) 2013-02-20
KR101534884B1 (ko) 2015-07-08
KR20150031489A (ko) 2015-03-24
CN108130327A (zh) 2018-06-08
KR20100065153A (ko) 2010-06-15
PT2206727E (pt) 2015-08-05
US20100209428A1 (en) 2010-08-19
IL204607A0 (en) 2010-11-30
AU2008311698A1 (en) 2009-04-16
BRPI0818437B1 (pt) 2021-03-30
US9090692B2 (en) 2015-07-28
CA2875310A1 (en) 2009-04-16
CN101896501A (zh) 2010-11-24
US20180037656A1 (en) 2018-02-08
AU2008311698C1 (en) 2014-03-06
US8546540B2 (en) 2013-10-01
HRP20150485T1 (en) 2015-06-19
EP2206727A1 (en) 2010-07-14
US10723800B2 (en) 2020-07-28
TW200927168A (en) 2009-07-01
CA2698326A1 (en) 2009-04-16
EP2907826A1 (en) 2015-08-19
PL2206727T3 (pl) 2015-08-31
NZ583397A (en) 2012-03-30
SG187523A1 (en) 2013-02-28
EP2907826B1 (en) 2018-05-30
JPWO2009048072A1 (ja) 2011-02-17
JP5845207B2 (ja) 2016-01-20
TWI511740B (zh) 2015-12-11
HK1145847A1 (en) 2011-05-06
SG10201605897RA (en) 2016-09-29
RU2012132678A (ru) 2014-02-10
SI2206727T1 (sl) 2015-06-30
KR101577935B1 (ko) 2015-12-16
JP6116652B2 (ja) 2017-04-19
JP2013144708A (ja) 2013-07-25
CN101896501B (zh) 2017-11-07
US10308715B2 (en) 2019-06-04
US20150344578A1 (en) 2015-12-03
JP2016074694A (ja) 2016-05-12
JP2017155044A (ja) 2017-09-07
JP6440759B2 (ja) 2018-12-19
EP2206727B1 (en) 2015-04-01
US20120251485A1 (en) 2012-10-04
AU2012201263A1 (en) 2012-03-22
MX2010003884A (es) 2010-04-30
IL234078B (en) 2018-08-30
US20120230988A1 (en) 2012-09-13
RU2010106639A (ru) 2011-08-27

Similar Documents

Publication Publication Date Title
HRP20150485T1 (en) ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15
PT3118220T (pt) Proteína
HK1146728A1 (en) Modified antibody constant region
ZA200906699B (en) Insecticidal proteins
GB0708002D0 (en) Antibodies
ZA201003131B (en) Anti-rsv g protein antibodies
SI2200700T1 (sl) Nova protitelesa
EP2138576A4 (en) ANTI-CLAUDIN-4 ANTIBODY
BRPI0814971A2 (pt) Proteína
EP2172483A4 (en) ANTI-MUC17 ANTIBODY
HK1153502A1 (en) Anti-bst2 antibody bst2
IL236236A (en) Antibodies to the fam26f polypeptide
GB0718737D0 (en) Antibodies
GB0702888D0 (en) Novel Antibodies
GB0815788D0 (en) Therapeutic antibodies
EP2324059A4 (en) THERAPEUTIC ANTI-PAMP ANTIBODIES
GB0719231D0 (en) Protein
GB0720563D0 (en) Protein
GB0700759D0 (en) Novel fusion protein
GB0704526D0 (en) Pathogenic protein
IL206541A0 (en) Novel protein
GB0719236D0 (en) Protein
GB0713302D0 (en) Protein
GB0709707D0 (en) Novel fusion protein
GB0724185D0 (en) Antibodies